Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas

[1]  K. Ganjoo,et al.  Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  W. Wilson,et al.  Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer , 2014, Molecular Cancer Therapeutics.

[3]  I. Tannock,et al.  Activity of the hypoxia‐activated pro‐drug TH‐302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy , 2014, International journal of cancer.

[4]  T. Nielsen,et al.  Pazopanib for metastatic soft-tissue sarcoma , 2012, The Lancet.

[5]  Tae-Min Kim,et al.  Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α , 2012, International journal of cancer.

[6]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[7]  Damien J. Ferraro,et al.  TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules , 2012, Cancer Chemotherapy and Pharmacology.

[8]  Damien J. Ferraro,et al.  Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer , 2011, Clinical Cancer Research.

[9]  P. Glazer,et al.  Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302 , 2011, Molecular Cancer Therapeutics.

[10]  P. Park,et al.  Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. , 2011, International journal of radiation oncology, biology, physics.

[11]  J. Bartek,et al.  More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance , 2011, Nature Cell Biology.

[12]  M. Kaag,et al.  Endothelial Membrane Remodeling Is Obligate for Anti-Angiogenic Radiosensitization during Tumor Radiosurgery , 2010, PloS one.

[13]  S. Schuetze,et al.  Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy? , 2009, The oncologist.

[14]  H. Taubert,et al.  A Three-Gene Signature for Outcome in Soft Tissue Sarcoma , 2009, Clinical Cancer Research.

[15]  T. Jacks,et al.  Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. , 2009, International Journal of Radiation Oncology, Biology, Physics.

[16]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[17]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[18]  M. Celeste Simon,et al.  The impact of O2 availability on human cancer , 2008, Nature Reviews Cancer.

[19]  D. Hanahan,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[20]  K. Williams,et al.  Antiangiogenics and radiotherapy , 2008, The Journal of pharmacy and pharmacology.

[21]  A. Lazar,et al.  Sarcoma epidemiology and etiology: potential environmental and genetic factors. , 2008, The Surgical clinics of North America.

[22]  F. McKeon,et al.  Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. , 2008, Cancer cell.

[23]  M. Koch,et al.  Tumor Escape from Endogenous, Extracellular Matrix–Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors , 2008, Clinical Cancer Research.

[24]  R. Hoffman,et al.  Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. , 2008, Journal of medicinal chemistry.

[25]  Jan Grimm,et al.  A spatially and temporally restricted mouse model of soft tissue sarcoma , 2007, Nature Medicine.

[26]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[27]  N. Segal,et al.  Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. , 2005, Cancer research.

[28]  A. Olshen,et al.  Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  A. Harris,et al.  Hypoxia Inducible Carbonic Anhydrase IX, Marker of Tumour: Hypoxia, Survival Pathway and Therapy Target , 2004, Cell cycle.

[30]  A. Dicker,et al.  Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  Zvi Fuks,et al.  Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.

[32]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Donald W Kufe,et al.  Vascular Endothelial Growth Factor Enhances Endothelial Cell Survival and Tumor Radioresistance , 2002, Cancer journal.

[34]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[35]  Ukcccr.  UKCCCR Guidelines for the Use of Cell Lines in Cancer Research , 2000, British Journal of Cancer.

[36]  T. Thangarajah,et al.  UKCCCR guidelines for the use of cell lines in cancer research , 1999, Cytogenetic and Genome Research.

[37]  R. Grimer,et al.  Management of Soft Tissue Sarcoma , 1990 .

[38]  G. Semenza,et al.  Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. , 1999, Annual review of cell and developmental biology.